Dexmedetomidine + Saline placebo
Phase 2/3Completed 0 watching 0 views this week📈 Rising
64
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Delirium
Conditions
Delirium
Trial Timeline
Feb 1, 2011 → Dec 1, 2013
NCT ID
NCT01151865About Dexmedetomidine + Saline placebo
Dexmedetomidine + Saline placebo is a phase 2/3 stage product being developed by Pfizer for Delirium. The current trial status is completed. This product is registered under clinical trial identifier NCT01151865. Target conditions include Delirium.
Hype Score Breakdown
Clinical
22
Activity
15
Company
9
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01151865 | Phase 2/3 | Completed |
Competing Products
17 competing products in Delirium
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lemborexant 5 mg + Control (placebo) group | Eisai | Phase 2 | 52 |
| Suvorexant + Placebo | Merck | Phase 3 | 77 |
| Suvorexant 20 mg + Placebo | Merck | Phase 2 | 52 |
| Rivastigmine + Placebo | Novartis | Approved | 85 |
| Rivastigmine prevention of delirium | Novartis | Phase 3 | 77 |
| Rivastigmine transdermal patch + placebo patch | Novartis | Phase 3 | 77 |
| Rivastigmine Patch | Novartis | Approved | 85 |
| Dexmedetomidine + Placebo | Pfizer | Phase 3 | 76 |
| Parecoxib | Pfizer | Approved | 84 |
| Dexmedetomidine + Placebo | Pfizer | Phase 3 | 76 |
| Pregabalin | Pfizer | Phase 3 | 76 |
| Dexmedetomidine + Midazolam | Pfizer | Phase 3 | 76 |
| Propofol + Dexmedetomidine | Pfizer | Pre-clinical | 22 |
| Cyclopofol + Propofol | Haisco Pharmaceutical Group | Approved | 82 |
| Dexmedetomidine + Sodium chloride 0.9% | Baxter | Phase 3 | 74 |
| Dexmedetomidine Hydrochloride Group | Brain Biotech | Approved | 77 |
| Dexmedetomidine sublingual film | BioXcel Therapeutics | Phase 2 | 44 |